Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
2023/03/20 by Laura A. Huppert, Ozge Gumusay, Özge Gümüşay +3 · 27 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Advanced Breast Cancer Therapies #HER2/EGFR in Cancer Research #Breast Cancer Treatment Studies
paper · doi:10.3322/caac.21777
Abstract
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%-70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data.
Citations
Cited by
- pH-responsive neutrophil membrane camouflage Ga–Mn bimetallic nanodecoy triggers apoptosis-immunity-metastasis suppression for tumor therapy
- Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2− breast cancer
- Introducción a los procesos geométricos infinitos y a las estructuras fractales
- Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements. [europepmc]
- Updated Review Article: Cyclin-Dependent Kinase 4/6 Inhibitor Impact, FDA Approval, and Resistance Pathways. [europepmc]
- STAT4 facilitates PD-L1 level via IL-12R/JAK2/STAT3 axis and predicts immunotherapy response in breast cancer. [europepmc]
- A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer. [europepmc]
- The prognostic implications and tumor-suppressive functions of CYR61 in estrogen receptor-positive breast cancer. [europepmc]
- Edaravone: A Novel Possible Drug for Cancer Treatment? [europepmc]
- Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions. [europepmc]
- A real-world clinicopathological model for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer. [europepmc]
- Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. [europepmc]
- CDK7 in breast cancer: mechanisms of action and therapeutic potential. [europepmc]
- Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs. [europepmc]
- PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. [europepmc]
- Green synthesis of zinc oxide nanoparticles using Rhus coriaria extract and their anticancer activity against triple-negative breast cancer cells. [europepmc]
- VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. [europepmc]
- Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer. [europepmc]
- The use of nanomaterials as drug delivery systems and anticancer agents in the treatment of triple-negative breast cancer: an updated review (year 2005 to date). [europepmc]
- Radiogenomics: bridging the gap between imaging and genomics for precision oncology. [europepmc]
- Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study. [europepmc]
- MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer. [europepmc]
- Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study. [europepmc]
- Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study. [europepmc]
- New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer-Current State and Molecular Pathology Perspective. [europepmc]
- Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2- breast cancer. [europepmc]
- Breast cancer: pathogenesis and treatments. [europepmc]
- A Systematic Review of Mechanisms, Incidence, and Management of Trastuzumab Deruxtecan Induced ILD/Pneumonitis in Solid Tumors. [europepmc]
Related